Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab in pediatric moderate to severe plaque psoriasis
2017-004515-39Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of secukinumab in plaque psoriasis, sponsored by Novartis. Primary endpoints: PASI 75 response at Week 12 and IGA mod 2011 0/1 response at Week 12. Started Jun 2018; status: completed.
02
Drugs
secukinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2017-004515-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004515-39.